WCN26-3993 ENSITRELVIR EXPOSURE IN COVID-19 PATIENTS ON HEMODIALYSIS (PROTECT-HD)

20260 citationsJournal Articlegold Open Access

Authors

Mineaki Kitamura · University of Nagasaki

Takahiro Takazono · Nagasaki University Hospital

Naoki Hosogaya · Nagasaki University Hospital

Shimpei Morimoto · Nagasaki University Hospital

Masahiro Kinoshita · Shionogi (Japan)

Eriko Hamada · Shionogi (United States)

Ryosuke Shimizu

Abstract

Patients on maintenance hemodialysis are highly vulnerable to severe COVID-19. Ensitrelvir, an oral SARS-CoV-2 3C-like protease inhibitor approved in Japan for COVID-19, has not been evaluated in patients on hemodialysis. Here we report real-world evidence on pharmacokinetics, antiviral activity and clinical effectiveness of ensitrelvir in patients on hemodialysis.

Topics & Keywords

COVID-19 Clinical Research Studies SARS-CoV-2 and COVID-19 Research Long-Term Effects of COVID-19

Publication Details

Published in: Kidney International Reports

Volume 11, Issue 4, pp. 104561-104561

DOI: 10.1016/j.ekir.2026.104561

Field-Weighted Citation Impact: 0.00

Command Palette

WCN26-3993 ENSITRELVIR EXPOSURE IN COVID-19 PATIENTS ON HEMODIALYSIS (PROTECT-HD)

Authors

Abstract

Topics & Keywords

Publication Details